Adapting smoking cessation treatment according to initial response to precessation nicotine patch

American Journal of Psychiatry

Volumn 170, Issue 8, 2013, Pages 860-867

  Rose, Jed E ^a   Behm, Frédérique M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; PLACEBO; VARENICLINE;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; PRIORITY JOURNAL; SMOKING CESSATION; SMOKING CESSATION PROGRAM; TACHYCARDIA; THORAX PAIN; TOBACCO DEPENDENCE; TREATMENT OUTCOME; VOMITING; WEAKNESS;

EID: 84883438163     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2013.12070919     Document Type: Article

References (20)

1. Bittoun R: A combination nicotine replacement therapy (NRT) algorithm for hard-to-treat smokers. J Smok Cessat. 2006; 1: 3-6
2. Hughes J: An algorithm for choosing among smoking cessation treatments. J Subst Abuse Treat 2008; 34: 426-432
3. Fiore MC: Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care 2000; 45: 1196-1199
4. Boshier A, Wilton LV, Shakir SA: Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol 2003; 59: 767-773
5. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group: Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47-55
6. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63
7. Simon JA, Duncan C, Carmody TP, Hudes ES: Bupropion for smoking cessation: a randomized trial. Arch Intern Med 2004; 164: 1797-1803
8. Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S: Suicidal behavior and depression in smoking cessation treatments. PLoS ONE 2011; 6:e27016
9. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K: Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166: 1571-1577
10. O'Malley SS: Varenicline and the evaluation of neuropsychiatric adverse events in smokers. Biol Psychiatry 2011; 69: 1017-1018
11. Singh S, Loke YK, Spangler JG, Furberg CD: Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011; 183: 1359-1366
12. Rose JE, Behm FM, Westman EC, Kukovich P: Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res 2006; 8: 89-101
13. Rose JE, Herskovic JE, Behm FM, Westman EC: Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment. Nicotine Tob Res 2009; 11: 1067-1075
14. Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR: Personalized smoking cessation: interactions between nicotine dose, dependence, and quit-success genotype score. Mol Med 2010; 16: 247-253
15. Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR: High-dose nicotine patch therapy: percentage of replacement and smoking cessation. JAMA 1995; 274: 1353-1358
16. Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Croghan IT, Hays JT, Lewis SF, Baker TB: Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995; 274: 1347-1352
17. Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB: Predicting smoking cessation: who will quit with and without the nicotine patch. JAMA 1994; 271: 589-594
18. Westman EC, Behm FM, Simel DL, Rose JE: Smoking behavior on the first day of a quit attempt predicts long-term abstinence. Arch Intern Med 1997; 157: 335-340
19. Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ, Kardinal CG, Knost JA, Tirona MT, Addo F, Morton RF, Michalak JC, Schaefer PL, Porter PA, Stella PJ: Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. J Clin Oncol 2003; 21: 914-920
20. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, David SP, Niaura R, Lerman C: Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 2008; 65: 683-693